Table 1 Demographic and clinical characteristics of stable and deterioration patients
|  | All patients N = 239 | Stable N = 177 | Deterioration N = 62 | P value |
|---|---|---|---|---|
Characteristics | Â | Â | Â | Â |
Age (years) [median (SD)], n (%) | 45.0 (15.9) | 41.5 (14.6) | 54.8 (15.5) | < 0.001 |
  ≤ 35 | 71 (29.7%) | 64 (36.2%) | 7 (11.3%) | < 0.001 |
 35–45 | 53 (22.2%) | 41 (23.2%) | 12 (19.4%) |  |
 45–55 | 61 (25.5%) | 46 (26.0%) | 15 (24.2%) |  |
  > 55 | 54 (22.6%) | 26 (14.7%) | 28 (45.2%) |  |
Gender, n (%) | Â | Â | Â | 0.956 |
 Female | 113 (47.3%) | 83 (46.9%) | 30 (48.4%) |  |
 Male | 126 (52.7%) | 94 (53.1%) | 32 (51.6%) |  |
Imput case (close contact with Wuhan), n (%) | Â | Â | Â | 0.981 |
 No | 141 (59.0%) | 105 (59.3%) | 36 (58.1%) |  |
 Yes | 98 (41.0%) | 72 (40.7%) | 26 (41.9%) |  |
Frequent breathing (cpm※) median [IQR] | 20.0 [20.0–21.0] | 20.0 [20.0–20.0] | 20.0 [20.0–22.0] | < 0.001 |
Blood pressure on admission (mmHg) [median (SD)] | Â | Â | Â | Â |
 Systolic pressure | 124 (13.0) | 123 (12.7) | 125 (13.9) | 0.295 |
 Diastolic pressure | 76.9 (9.80) | 76.6 (9.67) | 77.8 (10.2) | 0.396 |
Symptoms on admission | Â | Â | Â | Â |
Temperature (°C) median [IQR], n (%) | 38.0 [36.8–38.5] | 37.8 [36.6–38.4] | 38.3 [38.0–38.6] | < 0.001 |
 ≤ 37.3 | 65 (27.2%) | 60 (33.9%) | 5 (8.1%) | < 0.001 |
 37.3–38.0 | 67 (28.0%) | 51 (28.8%) | 16 (25.8%) |  |
 38.0–39.0 | 94 (39.3%) | 61 (34.5%) | 33 (53.2%) |  |
 > 39.0 | 13 (5.4%) | 5 (2.8%) | 8 (12.9%) |  |
Dyspnea, n (%) |  |  |  | < 0.001 |
 No | 177 (74.1%) | 161 (91.0%) | 16 (25.8%) |  |
 Yes | 62 (25.9%) | 16 (9.0%) | 46 (74.2%) |  |
Cough, n (%) | Â | Â | Â | 0.041 |
 No | 55 (23.0%) | 49 (27.7%) | 6 (9.68%) |  |
 Yes | 184 (77.0%) | 128 (72.3%) | 56 (90.3%) |  |
Headache, n (%) | Â | Â | Â | 0.564 |
 No | 203 (85.3%) | 152 (86.4%) | 51 (82.3%) |  |
 Yes | 35 (14.7%) | 24 (13.6%) | 11 (17.7%) |  |
Fatigue, n (%) |  |  |  | < 0.001 |
 No | 157 (66.0%) | 129 (72.9%) | 28 (45.9%) |  |
 Yes | 81 (34.0%) | 48 (27.1%) | 33 (54.1%) |  |
Muscle soreness, n (%) | Â | Â | Â | 0.372 |
 No | 210 (87.9%) | 158 (89.3%) | 52 (83.9%) |  |
 Yes | 29 (12.1%) | 19 (10.7%) | 10 (16.1%) |  |
Gastrointestinal symptoms (nausea, vomiting, diarrhea), n (%) | Â | Â | Â | 0.007 |
 No | 201 (84.1%) | 156 (88.1%) | 45 (72.6%) |  |
 Yes | 38 (15.9%) | 21 (11.9%) | 17 (27.4%) |  |
Incubation period (days) median [IQR] | 7.0 [5.0–9.0] | 7.0 [6.0–9.0] | 5.0 [4.0–7.8] | < 0.001 |
Length of hospital stay (days) median [IQR] | 13.0 (9.0–18.0) | 12.0 (9.0–17.5) | 17.5 (12.0–23.0) | < 0.001 |
Comorbidities, n (%) |  |  |  | < 0.001 |
 No | 161 (67.4%) | 137 (77.4%) | 24 (38.7%) |  |
 Yes | 78 (32.6%) | 40 (22.6%) | 38 (61.3%) |  |
Number of comorbidities median [IQR] | 0 [0–1] | 0 [0–1] | 1 [1, 2] | < 0.001 |
Respiratory system disease (COPD§, chronic bronchitis, emphysema, asthma and bronchiectasis), n (%) | 0.036 | |||
 No | 223 (93.3%) | 169 (95.5%) | 54 (87.1%) |  |
 Yes | 16 (6.69%) | 8 (4.52%) | 8 (12.9%) |  |
Cardiovascular diseases, n (%) | Â | Â | Â | 0.015 |
 No | 227 (95.0%) | 172 (97.2%) | 55 (88.7%) |  |
 Yes | 12 (5.02%) | 5 (2.82%) | 7 (11.3%) |  |
Endocrine system disease and metabolic related diseases (diabetes, obesity, hyperlipidemia and hyperthyroidism), n (%) | < 0.001 | |||
 No | 209 (87.4%) | 165 (93.2%) | 44 (71.0%) |  |
 Yes | 30 (12.6%) | 12 (6.78%) | 18 (29.0%) |  |
Hypertension, n (%) |  |  |  | < 0.001 |
 No | 205 (85.8%) | 162 (91.5%) | 43 (69.4%) |  |
 Yes | 34 (14.2%) | 15 (8.47%) | 19 (30.6%) |  |
Malignant tumour, n (%) |  |  |  | > 0.999 |
 No | 237 (99.2%) | 175 (98.9%) | 62 (100%) |  |
 Yes | 2 (0.8%) | 2 (1.1%) | 0 (0.00%) |  |
Digestive disease (hepatitis B, drug-induced hepatitis, fatty liver), n (%) | 0.364 | |||
 No | 225 (94.1%) | 168 (94.9%) | 57 (91.9%) |  |
 Yes | 14 (5.86%) | 9 (5.08%) | 5 (8.06%) |  |